CTLA4 and cancer: By targeting the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) pathways, ICIs enhance antitumor immune responses and have demonstrated unprecedented survival benefits in multiple cancer types, surpassing conventional chemotherapy and molecular targeted agents (3).